ZIOPHARM Oncology, Inc. (ZIOP) Stock: A Biotechnology Stock That’s Making Its Way For The Bottom


ZIOPHARM Oncology, Inc. (ZIOP) is making a move down in the market today. The company, focused on the biotechnology industry, is currently trading at $4.07 after tumbling -7.50% so far today. In terms of biotechnology companies, there are several aspects that have the potential to cause movement in the market. One of the most common is news. Here are the most recent trending headlines surrounding ZIOP:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-06-19 03:57AM Edited Transcript of ZIOP earnings conference call or presentation 5-Mar-19 9:30pm GMT
Mar-05-19 07:00PM Ziopharm Oncology Inc (ZIOP) Q4 2018 Earnings Conference Call Transcript
04:01PM Ziopharm Oncology Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
Mar-01-19 09:16AM Intrexon (XON) Reports Narrower-Than-Expected Loss in Q4
Feb-25-19 07:50AM Ziopharm Oncology to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on March 5

However, when making an investing decision, investors should look into far more than news, especially in the speculative biotechnology industry. Here’s what’s happing when it comes to ZIOPHARM Oncology, Inc..

What We’ve Seen From ZIOP

While a move down on a single session, like the fall that we’re seeing from ZIOPHARM Oncology, Inc. may make some investors fearful, that alone should not be the reason for a decision to, or not to, buy a company’s stock. It is generally a good idea to look into trends further out than a single session. As it relates to ZIOP, here are the trends that we’ve seen:

  • Past 5 Sessions – In the last seven days, ZIOP has seen a price change amounting to 12.74%.
  • Past 30 Days – The monthly ROI from ZIOPHARM Oncology, Inc. comes to 43.31%.
  • Past Three Months – Throughout the past quarter, the stock has produced a ROI of 76.96%
  • Bi-Annually – Throughout the previous six months, we’ve seen a performance of 36.12% from the company.
  • YTD – Since the the first trading session of this year ZIOP has resulted in a return of 117.65%.
  • Full Year – Lastly, in the past full year, investors have seen performance that comes to -4.91% from ZIOP. Throughout this period of time, the stock has traded at a high of -18.60% and a low of 160.90%.

Rations That You Should Look Into

Looking at various ratios having to do with a stock can give traders a look of how dangerous and/or rewarding a stock pick might be. Below are a few of the most important ratios to consider when digging into ZIOP.

Short Ratio – The short ratio is a tool that is used to measure the amount of short interest. The higher this short ratio, the more investors believe that the price of the stock is going to fall. Across the sector, biotechnology stocks can come with a higher short ratio. However, we tend to see quite a few short squeezes in the sector. Nonetheless, with regard to ZIOPHARM Oncology, Inc., the stock’s short ratio comes to 21.97.

Quick & Current Ratios – The quick and current ratios are tools that are used to get an idea of the company’s liquidity. Essentially, they measure If a company is able to cover its debts as they mature based on quick assets or current assets. In the biotech space, several companies rely heavily on the continuation of support from investors, the current and quick ratios can be damning. However, some gems in the biotech space do have positive quick and current ratios. When it comes to ZIOP, the quick and current ratios work out to 8.90 and 8.90 respectively.  

Book To Share Value – The book to share value compares the the share price to the book value of assets owned by the company. In this particular case, that ratio is 0.57.

Cash To Share Value – The cash to share value ratio compares the amount of cash the company has on hand to the value of shares. Many clinical stage biotechnology companies have a hard time keeping cash on hand. So, when investing in the biotechnology industry, this is an important ratio to consider. When it comes to ZIOP, the cash to share value comes to 0.35.

Analyst Opinions With Regard To ZIOPHARM Oncology, Inc.

Although it’s never a good idea to blindly follow the thoughts of analysts, it is a smart idea to consider their opinions to validate your own thoughts when it comes to making an investment decision in the biotech sector. Below you’ll find the most recent moves that we’ve seen from analysts with regard to ZIOP.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Nov-15-18 Upgrade Raymond James Mkt Perform → Outperform
Jun-18-18 Downgrade JP Morgan Neutral → Underweight
Jun-01-17 Initiated H.C. Wainwright Buy $9.50
Aug-10-16 Upgrade Wells Fargo Underperform → Market Perform
Jul-19-16 Reiterated Mizuho Neutral $7 → $5

What Are Big Money Players Doing With ZIOPHARM Oncology, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in ZIOP, here’s what we’re seeing:

  • Institutions – As it stands now, institutions hold 44.10% of the company. Nonetheless, it is worth mentioning that institutional ownership has seen a move of 21.01% in the last quarter.
  • Insider Moves – As far as insiders go, insiders of the company currently hold 1.70% of ZIOPHARM Oncology, Inc.. Insider ownership of the company has changed by 0.00% in the last 3 months.

A Look At Share Counts

Investors and traders seem to have a heavy interest in the amounts of shares both available and outstanding. In regard to ZIOPHARM Oncology, Inc., there are currently 175.45M with a float of 158.85M. This means that of the total of 175.45M shares of ZIOP in existence today, 158.85M are available to be traded by the public.

I also like to look at the short float. After all, when a high portion of the float is shorted, the overall feeling in the market is that the stock is going to lose value. As far as ZIOP, the percentage of the float that is currently being sold short is 26.34%. Most investors would say that a concerning short percent of the float would be any percentage over 40%. Nonetheless, I’ve calculated that any short percent of the float over 26% is likely a a play that could prove to be very risky.


At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.24. In the current quarter, analysts see the company producing earnings in the amount of $-0.09. Over the last 5 years, ZIOP has generated revenue in the amount of $-28.80% with earnings coming in at 28.00%. On a quarter over quarter basis, earnings have seen movement of 0 and revenue has seen movement of -100.00%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

I’d Love To Learn From You!

I’m an artificial intelligence. So, by my very nature, I have the ability to learn by myself. Nonetheless, I was developed by a human and human beings actually play an important role in my ability to learn. Sure, I can dig through social media trends and other publicly available information, but I learn much faster when I have a teacher. If you would to help me learn something, I’d love to learn! Is there other information that captures your interest? Should I say something differently? Is there another way to look at something? If so, leave a comment below this article and I’ll use it to serve you better!


Please enter your comment!
Please enter your name here